Download presentation
Presentation is loading. Please wait.
Published byTiffany Booth Modified over 9 years ago
1
Experimental Studies Randomized Trials Clinical Trials
2
Research Design Epidemiology Descriptive Studies Case Reports Case Series Cross Sectional Survey Analytic Studies Observational Studies Case-Control or Case-Comparison Cohort Studies Intervention Studies Clinical Trials
3
History The Islamic-Persian scholar Avicenna (980– 1037) was an early proponent of the technique. James Lind (1716–1794) ran a clinical trial in 1747 to compare the effects of cider, oranges and lemons and four other treatments in 12 patients suffering from scurvy (two assigned to each treatment). The two given oranges and lemons recovered. The first modern randomized clinical trials were carried out by the Medical Research Council in the United Kingdom and their prime mover was the statistician Austin Bradford Hill (1897– 1991).
4
From Canon of Medicine "The drug must be tested with two contrary types of diseases, because sometimes a drug cures one disease by Its essential qualities and another by its accidental ones." "The time of action must be observed, so that essence and accident are not confused." "The effect of the drug must be seen to occur constantly or in many cases, for if this did not happen, it was an accidental effect." "The experimentation must be done with the human body, for testing a drug on a lion or a horse might not prove anything about its effect on man."
6
Randomized Clinical Trials Therapeutic AZT treatment for AIDS Mastectomy vs. lumpectomy Intervention Mammography for early detection Cholesterol lowering drugs Prevention Smoking cessation Clean needle program
7
Strength of Evidence WeakerStronger Case reports Randomized Case series Trials Observational studies Case/Control Cohort
8
Experimental Studies General features inherent to methodology prospective concurrent control group intervention with placebo or usual care investigator controls/ manipulates conditions studied (hence an experiment) investigator assigns exposure
9
Schematic diagram of a clinical trial Sample Nonparticipants Randomization Control Intervention Lost to follow-up Measure outcome
10
Randomization types Simple Systematic Balanced block Stratified
11
Simple randomization BBABABAABB BAAAAAAABA BABABBBBAB ABABABBBBB BAAABABBAA AABABBBABB ABBAABBBAB BAAABBABBB BAABABBBAB BBABBBBABA
12
Systematic randomization ABABABABAB ABABABABAB ABABABABAB ABABABABAB ABABABABAB ABABABABAB ABABABABAB ABABABABAB ABABABABAB ABABABABAB
13
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396
14
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396
15
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABB
16
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABB
17
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABBABBA
18
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABBABBA
19
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABBABBA ABAB
20
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABBABBA ABAB
21
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABBABBA ABABAABB
22
Balanced block randomization 1.AABB 2.ABAB 3.ABBA 4.BBAA 5.BABA 6.BAAB 13291 64387 31258 24173 45396 AABBABBA ABABAABB BAABBBAA ABBAABBA AABBABAB BABAABBA BBAAAABB ABBABBAA BABAABBA BAABAABB
23
Confounding and Bias By randomly assigning the exposure - reduce the risk of confounding because: “confounders - known and unknown” are randomly distributed among the treatment groups By blinding (masking) assessment of outcome reduce the risk of information bias
24
Masking (blinding) To avoid systematic differences between the treated and control groups during the course of the study in factors other than the one under study Double-blind Patient, care provider, and investigator (person collecting data) all unaware of treatment assignment Single-blind Patient unaware of treatment assignment
25
Blindness Open label (unblinding) Single blinding (patients only) Double blinding (patients and investigators) Triple blinding (patients and investigators and Monitoring investigators)
26
Concerns in RCT Loss to follow up Low compliance Publication bias
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.